Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

White Blood Cell Count Predicts Response to Lung Cancer Immunotherapy

05 May 2017
Cancer Prevention;  Immunotherapy
Thoracic Malignancies

Presentations at ELCC 2017

Geneva, Switzerland – White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research to be presented at the European Lung Cancer Conference (ELCC).

“Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some – but not all – patients with non-small cell lung cancer (NSCLC),” said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. “Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond.”

He continued: “PD-L1 expression in a biopsy of tumour tissue is used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of immune response.”

This study assessed the ability of white blood cell counts to predict whether lung cancer patients responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days. White blood cell counts were performed at baseline, after two nivolumab cycles, and after four nivolumab cycles. The researchers compared white blood cell counts between responders and non-responders to nivolumab.

The researchers found that white blood cell counts at baseline and during therapy predicted whether patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment. Responders to nivolumab also had a greater number and concentration of CD8 positive T cells that expressed PD-1.

Tiseo said: “The number and function of natural killer cells and the frequency of PD-1 expression in CD8 positive T cells could be predictive biomarkers for nivolumab treatment in advanced NSCLC. The identification of a panel of blood predictive biomarkers would enable the early identification of patients most likely to benefit from anti-PD-1 and anti-PD-L1 treatment.”

Commenting on the findings, Dr Stefan Zimmermann, Senior Consultant, Medical Oncology Department, HFR – Hôpital Cantonal, Fribourg, Switzerland, said: “In the current era of precision medicine and increasing healthcare costs we urgently need proper predictive biomarkers to select patients that will benefit from a specific therapy.”

He continued: “This study found that baseline levels of certain white blood cells do have a role in predicting response to immunotherapy in patients with lung cancer. These new factors should be investigated in future clinical trials, together with tumour PD-L1 expression and other markers that constitute the cancer immunogram predict whether or not patients will benefit from treatment.”

-END-

Notes to Editors

References

Abstract 30PD - ‘Circulating immune-profile as predictor of outcome in NSCLC patients treated with Nivolumab’ will be presented by Dr Marcello Tiseo during the Poster Discussion session ‘Epidemiology and innovations in biomarker development’ on Saturday, 6 May, 16:45 (CEST).

About the European Lung Cancer Conference (ELCC) 2017

The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancers. It is organised by the European Society for Medical Oncology and the International Association for the Study of Lung Cancer in partnership with ESTRO and ETOP.

ELCC provides a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2,000 attendees are expected from throughout Europe and the rest of the world.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

About the International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.

Last update: 05 May 2017

Disclaimer

This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO or IASLC who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.